# US 2018/0021411 A1 · Composition and Method for Improving Sleep Duration and Quality

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021411 A1
- Document ID: US20180021411A1
- Status: Published application
- Kind: A1
- Application number: 15/625,777
- Filed: 2017-06-16
- Published: 2018-01-25
- Earliest claimed: 2016-07-20
- Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Inventors: Jack N. Losso; Jose Daniel Estrada Andino
- Web page: https://patentgrep.com/patent/US20180021411A1

## CPC

- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/28: Compounds containing heavy metals
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/365: Lactones
- A61K 31/728: Hyaluronic acid
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An intervention for sleep disorders comprises: collagen, a gelatin peptide, or the amino acid glycine; L-theanine; lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative; hyaluronic acid; epigallocatechin gallate; and quinic acid. The intervention helps regulate pro-inflammatory biomarkers that are often associated with insomnia development and progression. These biomarkers include cytokines and enzymes associated with tryptophan degradation. Inhibition of these enzymes and cytokines improves tryptophan availability and sleep quality, and allows individuals to sleep better with fewer side effects. The composition promotes high-quality, deep sleep.

## Claims

### Claim 1

A composition comprising:
(a) a first component selected from one or more of the following: collagen, a gelatin peptide, or the amino acid glycine; wherein said first component has a molecular weight less than 3500 Dalton;
(b) a second component comprising L-theanine;
(c) a third component comprising lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative;
(d) a fourth component comprising hyaluronic acid;
(e) a fifth component comprising epigallocatechin gallate; and
(f) a sixth component comprising quinic acid.
